Skip to content
Search

Latest Stories

STADA appoints Nigel Stephenson to lead UK business

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023.

Based in Huddersfield, UK, Stephenson will report directly to STADA’s Head of Western Europe and Germany, Stephan Eder.


He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA’s Mid-Sized European Markets.|

A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies.

He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland.

“With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership,” stated Eder.

“Building on the strong progress made under Rudolf Bär over the past year, I am confident that Nigel will lead our team in the UK to deliver strong, sustainable growth.”

Stephenson started his career as part of the IBM Global Leaders Program in the US. He then worked for more than 9 years at Procter & Gamble, spanning local and regional marketing roles for key brands such as Ariel, before subsequently taking over cross-regional and global marketing responsibilities.

He continued his personal growth at two renowned global healthcare companies, Novartis and GSK, developing from leading regional and global marketing roles in Switzerland and Poland to general management positions for Romania & Moldova and Switzerland. In his last position as General Manager Switzerland at Haleon, Nigel successfully demonstrated exceptional leadership skills and achieved significant growth for the organization.

“I am looking forward to further strengthening the STADA growth mindset in UK, working on iconic brands such as Covonia, Care, Cetraben, Hedrin, Oilatum and Zoflora, as well as our growing Generics and Specialty portfolios in the UK,” Stephenson commented.

“Based on the strong commercial performance, product launches and employee engagement achieved under Rudolf’s leadership, I am sure that our high-performance team will continue to deliver sustainable growth and to outperform the industry.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less